Elevance Health Inc.
ELVNYSEHealthcare● Active
$415.53
+$6.09(+1.49%)
Market Cap$90.2B
P/E Ratio—
52W High$416.56
52W Low$273.71
Elevance Health Inc. (ELV) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
ELV · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: Apr 22, 2026EPS Actual
$12.58
Est. $10.68 · +17.8%
Revenue
$49.49B
Est. $48.20B · +2.7%
Fiscal Period
Q2 FY2026
FY ends December
Report Date
Apr 22, 2026
After Market Close
▲ Beat EPS▲ Beat Revenue✓ 3-Quarter EPS Beat Streak
ELV reports quarterly as a NYSE-listed Medical - Healthcare Plans company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$0.07
Rev. $15.39B
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$0.07
Rev. Est.$15.39B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Jul 16, 2026 | $6.16 | — | — | — | $48.80B | — |
| ▲ Q2 FY2026 | Apr 22, 2026 | $10.68 | $12.58 | +17.8% | $49.49B | $48.20B | +2.7% |
| ▲ Q1 FY2026 | Jan 28, 2026 | $3.10 | $3.33 | +7.4% | $49.31B | $49.84B | -1.1% |
| ▲ Q4 FY2025 | Oct 21, 2025 | $4.93 | $6.03 | +22.3% | $50.71B | $49.38B | +2.7% |
| — Q3 FY2025 | Jul 17, 2025 | $8.91 | $8.84 | -0.8% | $49.78B | $48.19B | +3.3% |
| ▲ Q2 FY2025 | Apr 22, 2025 | $11.41 | $11.97 | +4.9% | $48.89B | $46.30B | +5.6% |
| ▲ Q1 FY2025 | Jan 23, 2025 | $3.80 | $3.84 | +1.1% | $45.44B | $44.95B | +1.1% |
| ▼ Q4 FY2024 | Oct 17, 2024 | $9.66 | $8.37 | -13.3% | $45.15B | $43.47B | +3.9% |
Q3 FY2026
Jul 16, 2026
EPS Actual
—
EPS Est.
$6.16
EPS Surpr.
—
Revenue
—
Q2 FY2026
Apr 22, 2026Beat
EPS Actual
$12.58
EPS Est.
$10.68
EPS Surpr.
+17.8%
Revenue
$49.49B
Q1 FY2026
Jan 28, 2026Beat
EPS Actual
$3.33
EPS Est.
$3.10
EPS Surpr.
+7.4%
Revenue
$49.31B
Q4 FY2025
Oct 21, 2025Beat
EPS Actual
$6.03
EPS Est.
$4.93
EPS Surpr.
+22.3%
Revenue
$50.71B
Q3 FY2025
Jul 17, 2025
EPS Actual
$8.84
EPS Est.
$8.91
EPS Surpr.
-0.8%
Revenue
$49.78B
Q2 FY2025
Apr 22, 2025Beat
EPS Actual
$11.97
EPS Est.
$11.41
EPS Surpr.
+4.9%
Revenue
$48.89B
Q1 FY2025
Jan 23, 2025Beat
EPS Actual
$3.84
EPS Est.
$3.80
EPS Surpr.
+1.1%
Revenue
$45.44B
Q4 FY2024
Oct 17, 2024Miss
EPS Actual
$8.37
EPS Est.
$9.66
EPS Surpr.
-13.3%
Revenue
$45.15B
Analyst Estimates
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2028 | $5.57 | $5.81 | $6.02 | 9 |
| Q3 FY2028 | $6.90 | $7.20 | $7.47 | 9 |
| Q2 FY2028 | $7.55 | $7.87 | $8.17 | 12 |
| Q1 FY2028 | $12.74 | $13.29 | $13.79 | 9 |
| Q4 FY2027 | $3.84 | $4.00 | $4.16 | 8 |
| Q3 FY2027 | $5.84 | $6.09 | $6.32 | 13 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2028 | $50.0B | $51.6B | $53.1B | 6 |
| Q3 FY2028 | $50.8B | $52.4B | $53.9B | 11 |
| Q2 FY2028 | $50.4B | $52.1B | $53.6B | 6 |
| Q1 FY2028 | $50.9B | $52.6B | $54.1B | 6 |
| Q4 FY2027 | $48.1B | $49.6B | $51.1B | 7 |
| Q3 FY2027 | $48.6B | $50.2B | $51.6B | 8 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q2 FY2026 | Apr 22, 2026 | +17.8% | $328.11 | $328.20 | +0.03% |
| ▲ Q1 FY2026 | Jan 28, 2026 | +7.4% | $322.92 | $341.85 | +5.86% |
| ▲ Q4 FY2025 | Oct 21, 2025 | +22.3% | $354.07 | $349.75 | -1.22% |
| ▲ Q3 FY2025 | Jul 17, 2025 | -0.8% | $344.55 | $302.45 | -12.22% |
| ▲ Q2 FY2025 | Apr 22, 2025 | +4.9% | $406.69 | $415.90 | +2.26% |
| ▲ Q1 FY2025 | Jan 23, 2025 | +1.1% | $390.73 | $401.36 | +2.72% |
| ▼ Q4 FY2024 | Oct 17, 2024 | -13.3% | $496.96 | $444.35 | -10.59% |
| ▲ Q3 FY2024 | Jul 17, 2024 | +1.1% | $553.14 | $520.93 | -5.82% |
Q2 FY2026+0.03%
Report Date
Apr 22, 2026
EPS Beat/Miss
+17.8%
Price Before
$328.11
Price After
$328.20
Q1 FY2026+5.86%
Report Date
Jan 28, 2026
EPS Beat/Miss
+7.4%
Price Before
$322.92
Price After
$341.85
Q4 FY2025-1.22%
Report Date
Oct 21, 2025
EPS Beat/Miss
+22.3%
Price Before
$354.07
Price After
$349.75
Q3 FY2025-12.22%
Report Date
Jul 17, 2025
EPS Beat/Miss
-0.8%
Price Before
$344.55
Price After
$302.45
Q2 FY2025+2.26%
Report Date
Apr 22, 2025
EPS Beat/Miss
+4.9%
Price Before
$406.69
Price After
$415.90
Q1 FY2025+2.72%
Report Date
Jan 23, 2025
EPS Beat/Miss
+1.1%
Price Before
$390.73
Price After
$401.36
Q4 FY2024-10.59%
Report Date
Oct 17, 2024
EPS Beat/Miss
-13.3%
Price Before
$496.96
Price After
$444.35
Q3 FY2024-5.82%
Report Date
Jul 17, 2024
EPS Beat/Miss
+1.1%
Price Before
$553.14
Price After
$520.93
Avg Beat Reaction-1.20%
Avg Miss Reaction-10.59%
Beat Rate7 / 8 quarters
Largest Move-12.22% (Q3 FY2025)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: ELV ends December
Elevance Health Inc. (ELV) most recently reported earnings on April 22, 2026 for Q2 FY2026, posting EPS of $12.58 — beating the analyst consensus of $10.68 by +17.8%. ELV has beaten EPS estimates for 3 consecutive quarters. The next ELV earnings date is expected around September 1, 2026.
Each quarter, investors track ELV earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. ELV revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
ELV's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
ELV earnings · 5 questionsElevance Health Inc.'s next earnings report is expected around September 1, 2026. ELV typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; ELV historically reports after market close (AMC).
ELV earnings datewhen is ELV earningsELV next earnings datewhen does ELV report earningsELV earnings calendar
▸ Source: FMP · Elevance Health Inc. SEC filings · US GAAP · Elevance Health Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026